Breaking News

Scintilla Bolsters Pain Management Biz

Acquires Scilex Pharmaceuticals to add a late-stage asset to its portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Scintilla Pharmaceuticals, a subsidiary of Sorrento Therapeutics, has acquired Scilex Pharmaceuticals. Scintilla’s lead program is resiniferatoxin (RTX) for the treatment of intractable cancer pain. Scilex, based in Malvern, PA, is engaged in the development and commercialization of products focused on the treatment of pain. Its lead product candidate, ZTlido (lidocaine patch 1.8%), is a branded lidocaine patch formulation being developed for the treatment of postherpetic neuralgia, the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters